Related Experiment Video

Updated: Mar 10, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K

[Portopulmonary hypertension: Updated review]

Nielzer Rodríguez-Almendros1, Liz N Toapanta-Yanchapaxi2, Jonathan Aguirre Valadez2

  • 1Departamento de Hipertensión Pulmonar y Función Ventricular Derecha, UMAE Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, D.F., México.

Archivos De Cardiologia De Mexico
|December 18, 2016
PubMed

Insights

Portopulmonary hypertension (PPH), a rare condition, is poorly understood in Mexico despite high rates of chronic liver disease. Early diagnosis via echocardiogram and right cardiac catheterisation is vital for liver transplant candidates.

Area of Science:

  • Cardiology
  • Hepatology
  • Pulmonology

Background:

  • Portopulmonary hypertension (PPH) is a rare complication of chronic liver disease, with unknown prevalence in Mexico.
  • PPH is the fourth most frequent subtype of pulmonary arterial hypertension.
  • Chronic liver diseases are highly prevalent in Mexico, suggesting a potential underdiagnosis of PPH.

Purpose of the Study:

  • To highlight the diagnostic challenges and clinical significance of Portopulmonary hypertension (PPH) in Mexico.
  • To emphasize the impact of PPH on orthotopic liver transplantation (OLT) outcomes.
  • To discuss current therapeutic strategies and future considerations for PPH management.

Main Methods:

  • Diagnosis relies on echocardiogram and right cardiac catheterisation in patients with suspected pulmonary hypertension or awaiting OLT.
  • Assessment of PPH severity is crucial for determining OLT candidacy and perioperative risk.
  • Review of existing literature on PPH diagnosis, management, and transplantation outcomes.

Main Results:

  • PPH significantly increases perioperative mortality in OLT candidates.
  • Specific therapies can improve outcomes for OLT candidates with moderate to severe PPH.
  • PPH can be an absolute contraindication for OLT.

Conclusions:

  • Accurate diagnosis and management of PPH are critical for improving outcomes in liver disease patients, especially OLT candidates.
  • Therapeutic interventions are essential for managing PPH and optimizing OLT success.
  • The role of combined lung-liver or heart-lung-liver transplantation for PPH requires further investigation.
Keywords:
Cirrosis hepáticaHipertensión arterial pulmonarLiver cirrhosisLiver transplantationMexicoMéxicoPulmonary arterial hypertensionTrasplante de hígado

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.5K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
751
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
610
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
698
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
674
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.0K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
578